A new Phase 3 clinical trial involving goserelin was registered on August 20, 2026. The trial, titled "ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)," is listed under identifier NCT07777263.
According to the registration, the study is currently in Phase 3 and has a status of not yet recruiting. The trial title indicates a focus on androgen deprivation therapy de-escalation in a selected population of high-risk prostate cancer patients, conducted as part of a GROUQ led PCS study series.
No additional details such as recruitment timelines, enrollment criteria, or outcome measures were included in the available event data. No results have been posted for this trial. This update reflects only the registration status as of the date listed and does not indicate any findings, efficacy, or safety conclusions regarding goserelin.
Readers seeking further context on goserelin, including its approved regulatory status and general background, can consult the compound overview.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT07777263"]